Abbott (NYSE:ABT) announced today that it issued a device correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors ...

NORTH CHICAGO (dpa-AFX) - Abbott (ABT) announced Monday that the U.S. Food and Drug Administration has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring or ...

Abbott issued a medical device correction for some of its glucose sensors after internal testing found that some sensors may ...

Tandem’s Control-IQTM hybrid closed-loop technology now integrates with the 15-day continuous glucose monitoring sensor. This ad will auto-close in 10 seconds ...

ABBOTT PARK, Ill. & SAN DIEGO--(BUSINESS WIRE)--Abbott (NYSE: ABT), the global health care company, and Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

Ambrosia Systems, a fast growing medical technology company, announced the launch of the next version of NightRider BluCon to work with FreeStyle Libre 2 sensor. The new NightRider BluCon also works ...

Abbott announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval fromHealth Canada for adults and children (4 and older) with diabetes. With new ...

MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...